Swiss Personal Products Stock News

If you are wondering whether Partners Group Holding is currently offering fair value or a potential opportunity, looking closely at its valuation can help put the recent share price in context. The stock closed at CHF 852.60, with returns of 9.6% decline over 7 days, 20.2% decline over 30 days, 17.2% decline year to date, 33.2% decline over 1 year, 7% return over 3 years and 11.2% decline over 5 years. These moves may have changed how the market views its risk and potential. Recent coverage...

PSP Swiss Property recently reported its 2025 results, with net income rising on property revaluations, a portfolio of about CHF 10.10 billion, and a proposed dividend increase to CHF 3.95 per share. An interesting angle is that the higher dividend comes even as underlying earnings softened, underscoring management’s reliance on revaluation gains and confidence in funding major redevelopment projects from a strong balance sheet. We’ll now examine how the higher dividend proposal, underpinned...

FDA filing for breast cancer drug puts Roche Holding (SWX:ROG) in focus Roche Holding (SWX:ROG) is back on investors’ radar after the U.S. FDA accepted its New Drug Application for giredestrant in ER positive, HER2 negative, ESR1 mutated advanced breast cancer. The filing, supported by phase III evERA Breast Cancer data, comes alongside positive readouts for Gazyva in kidney disease and constructive industry views on next generation sequencing and genetic testing, areas where Roche is an...

If you are wondering whether Nestlé shares still justify their price, you are not alone; the stock often attracts investors who care about what they are actually paying for each franc of underlying business. Nestlé shares last closed at CHF81.40, with returns of 1.5% over 7 days, 12.3% over 30 days, 6.5% year to date, and a 3.9% decline over 1 year, 17.8% decline over 3 years, and 3.3% decline over 5 years, hinting at changing views on its growth and risk profile. Recent headlines around...

Zug Estates Holding (SWX:ZUGN) drew fresh investor attention after reporting full year 2025 results, with revenue of CHF 91.5 million, net income of CHF 85.18 million, and an announced annual dividend of CHF 49 per share. See our latest analysis for Zug Estates Holding. The share price has climbed to CHF 2,400, with an 8.11% 1 month share price return and 11.63% 3 month share price return. The 1 year total shareholder return of 19.75% suggests momentum has been building over a longer...

If you are wondering whether Cosmo Pharmaceuticals at CHF116.20 is priced attractively or already baking in a lot of optimism, this article walks through what the numbers say about its value. The stock shows returns of 0.5% over 7 days, 1.8% over 30 days, 10.2% year to date, 76.5% over 1 year, 105.4% over 3 years and 53.4% over 5 years, which may prompt questions about how much of this performance is supported by fundamentals. Recent coverage has focused on Cosmo Pharmaceuticals' position...

Amrize (SWX:AMRZ) has drawn fresh attention after issuing upbeat 2026 revenue guidance, outlining both ordinary and special dividend proposals, and attracting supportive analyst commentary following its recent spin off. See our latest analysis for Amrize. After the guidance, dividend proposals and recent board and auditor changes, Amrize’s 7 day share price return of 9.34% and 90 day share price return of 20.79% suggest building positive momentum from a starting point of CHF49.15. If this has...

Event driven repositioning at Partners Group Holding Partners Group Holding (SWX:PGHN) is in focus after shifting capital away from technology and software toward AI linked infrastructure assets, while its open ended private credit funds avoided net redemptions during recent sector volatility. See our latest analysis for Partners Group Holding. The recent repositioning toward AI linked infrastructure comes after a mixed run for investors, with a 30 day share price return of 14.25% decline, a...

Cembra Money Bank AG has already reported its full-year 2025 results, with net interest income of CHF 372.16 million and net income of CHF 179.57 million, and announced an annual dividend of CHF 4.60 per share, ex-date April 28, 2026. While net interest income eased slightly from the prior year, higher net income and an increased dividend highlight the bank’s ability to convert its lending activities into growing shareholder distributions. Next, we’ll examine how the higher net income and...

Sika (SWX:SIKA) has wrapped up FY 2025 with Q4 revenue of CHF 2.6b and net income of CHF 174.1m, while Q4 basic EPS came in at CHF 1.09. Over the past few quarters, the company has reported revenue of CHF 2.8b and EPS of CHF 2.02 in Q4 2024, CHF 2.9b in Q3 2025, and CHF 2.6b in Q4 2025. This sets up a results season where investors are likely to focus on how these changes in revenue and EPS relate to margins. See our full analysis for Sika. With the latest figures on the table, the next step...

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

This article is designed to help you think clearly about whether Alcon's current share price fairly reflects its potential or if the market might be mispricing it. Alcon closed at $61.90, with a 1.4% gain over the last 7 days, a 3.2% decline over 30 days, a 2.6% decline year to date, and a 23.6% decline over the past year, which may catch the eye of investors reassessing the balance between opportunity and risk. Recent headlines around Alcon have focused on its position within healthcare and...

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.

If you are wondering whether ABB is still fairly priced after a strong run, this article will walk through what the current share price might be implying about value. ABB's share price closed at CHF 69.80, with returns of 1.7% over 7 days, 13.3% over 30 days, 14.0% year to date, 34.5% over 1 year, 139.7% over 3 years and 215.6% over 5 years. This raises the question of what is already reflected in the price. Recent news around ABB has focused on its position as a global industrial technology...

In early February 2026, Novartis reported final Phase III ALIGN data showing Vanrafia® (atrasentan) slowed kidney function decline in adults with IgA nephropathy, alongside a new long-term Actinium-225 supply agreement from Niowave to support its radioligand therapy portfolio for difficult-to-treat cancers. Together, these updates highlight Novartis’ effort to build depth in both renal disease and radiopharmaceutical oncology, reinforcing the importance of specialized therapies and secure...

As European markets navigate volatility, with the STOXX Europe 600 Index recently hitting a new high before settling nearly unchanged, investors are keenly observing economic indicators such as employment growth and GDP expansion in the eurozone. Amidst these dynamics, dividend stocks have gained attention for their potential to provide steady income; qualities like strong cash flow and a history of consistent payouts can make them appealing choices in uncertain market conditions.

The market seemed underwhelmed by the solid earnings posted by Schindler Holding AG ( VTX:SCHN ) recently. Our analysis...

In February 2026, Lindt & Sprüngli confirmed the return of its sold‑out DubaiStyle Chocolate to Canadian shelves, reintroducing the 150g bar and adding a new 40g snackable format crafted with smooth milk chocolate, pistachio filling and kadayif pastry. The launch of a portable 40g DubaiStyle bar alongside the original 150g format highlights how Lindt is using premium, culturally inspired recipes to broaden everyday indulgence occasions. We’ll now examine how expanding DubaiStyle into a new...

As European markets experience volatility amidst global concerns about AI disruption and economic data releases, the pan-European STOXX Europe 600 Index has managed to reach new highs, reflecting a complex investment landscape. In such an environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate these uncertain times.

Board overhaul puts Lonza Group (SWX:LONN) governance in focus Lonza Group (SWX:LONN) has set out a broad board refresh, nominating tech-focused leader Sami Atiya and proposing Claudia Süssmuth-Dyckerhoff as Vice-Chair while several long-serving directors prepare to step down. See our latest analysis for Lonza Group. The board refresh headlines come at a time when Lonza Group’s 1-day share price return of 1.19% and 7-day share price return of 2.21% sit against a 1-year total shareholder...

Idorsia (SWX:IDIA) is back on investors’ radar after securing regulator alignment in the US and Europe on a streamlined Phase 3 registration program for its Fabry disease candidate, lucerastat. See our latest analysis for Idorsia. The latest lucerastat update lands after a sharp swing in sentiment, with Idorsia’s 1 year total shareholder return very large at about 5.3x. However, the year to date share price return is slightly negative and longer term total shareholder returns over 3 and 5...

With a median price-to-earnings (or "P/E") ratio of close to 21x in Switzerland, you could be forgiven for feeling...